Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Viruses that replicate in the human respiratory mucosa without infecting systemically,
including influenza A, SARS-CoV-2, endemic coronaviruses, RSV, and many other" …

Background: Observational and small, randomized studies suggest that influenza vaccine
may reduce future cardiovascular events in patients with cardiovascular disease. Methods …

Importance Influenza infection is associated with increased cardiovascular hospitalization
and mortality. Our prior systematic review and meta-analysis hypothesized that influenza …

Background Influenza infection causes considerable morbidity and mortality in patients with
cardiovascular disease. We assessed the effects of the influenza vaccine on mortality and …

This report updates the 2020–21 recommendations of the Advisory Committee on
Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the …

Background The relative vaccine effectiveness (rVE) of high-dose quadrivalent influenza
vaccines (QIV-HD) versus standard-dose quadrivalent influenza vaccines (QIV-SD) against …

Importance The gold standard for outcome adjudication in clinical trials is medical record
review by a physician clinical events committee (CEC), which requires substantial time and …

Abstract Purpose of Review Influenza infection is a significant, well-established cause of
cardiovascular disease (CVD) and CV mortality. Influenza vaccination has been shown to …

Aims Previous studies show a reduced incidence of first myocardial infarction and stroke 1–
3 months after influenza vaccination, but it is unclear how underlying cardiovascular risk …